OTCM
PLSH
, Last price
USD
Name
Panacea Life Sciences Holdings Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Panacea Life Sciences Holdings, Inc. operates as an integrated research and production firm, specializing in cannabinoid and nutraceutical products across the entire supply chain, from sourcing to final sale. Its core mission is to develop and deliver natural, pharmaceutical-grade alternatives for both human and pet consumption. The company's diverse product range encompasses items such as softgels, edible gummies, liquid tinctures, sublingual tablets, and a variety of cosmetic and topical applications. In addition to these offerings, the company is involved in the personal protective equipment (PPE) market, importing and distributing hand sanitizers and masks. Panacea Life Sciences also provides white-label and contract manufacturing services to other cannabinoid companies, sells raw materials, and manages tolling arrangements. Established in 2008, the company is headquartered in Greenwood Village, Colorado.
Key people
James Sposato
Chief Information Officer · since 2019
Alvaro Daniel Alberttis
Director · since 2020
Daniel Alberttis
Director · since 2020
Kenneth E Puzder
Chief Financial Officer, Director · since 2019
Timothy John Ryan
Executive Vice President, Director · since 2016
Vladislav Yampolsky
Interim Executive Chairman of the Board · since 2019
Independent Director · since 2019
John C. Price
Independent Director · since 2019
Independent Director · since 2019
Legal address
C/O Corporate Creations Network Inc.
8275 South Eastern Avenue
Suite 200
Las Vegas, NV 89123
US
8275 South Eastern Avenue
Suite 200
Las Vegas, NV 89123
US
Headquarters
5510 Merrick Road
Massapequa, NY 11758
US
Massapequa, NY 11758
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||